Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

BACKGROUND: Gemcitabine is used to treat a wide range of tumours, but its efficacy is limited by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate modification of gemcitabine, is the first anti-cancer ProTide to enter the clinic and is designed to overcome these key resistance mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Blagden, Sarah P., Rizzuto, Ivana, Suppiah, Puvan, O’Shea, Daniel, Patel, Markand, Spiers, Laura, Sukumaran, Ajithkumar, Bharwani, Nishat, Rockall, Andrea, Gabra, Hani, El-Bahrawy, Mona, Wasan, Harpreet, Leonard, Robert, Habib, Nagy, Ghazaly, Essam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189138/
https://www.ncbi.nlm.nih.gov/pubmed/30206366
http://dx.doi.org/10.1038/s41416-018-0244-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189138/
https://www.ncbi.nlm.nih.gov/pubmed/30206366
http://dx.doi.org/10.1038/s41416-018-0244-1

Ejemplares similares